{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:10:46Z","timestamp":1791259846645,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","award":["Harrison Pennicott Scholarship"],"award-info":[{"award-number":["Harrison Pennicott Scholarship"]}],"id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Australian College of Physicians","award":["D.E.V. Starr Research Establishment Fellowship"],"award-info":[{"award-number":["D.E.V. Starr Research Establishment Fellowship"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1197169"],"award-info":[{"award-number":["1197169"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1176538"],"award-info":[{"award-number":["1176538"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and\/or the presence of reflux oesophagitis diagnosed endoscopically. The impact of GORD and its treatment on ILD features (including severity and time to ILD development) and survival was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GORD was a common manifestation affecting 1539\/1632 (94%) of SSc patients. GORD affected 450\/469 (96%) of those with SSc-ILD cohort. In SSc-ILD, there was no relationship between the presence of GORD or its treatment and time to ILD development or ILD severity. However, GORD treatment was associated with improved survival in those with ILD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Combination therapy with both a PPI and a H2RA was associated with a greater survival benefit than single agent therapy with PPI alone (HR 0.3 vs 0.5\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.050 respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GORD is a common SSc disease manifestation. While the presence or treatment of GORD does not influence the development or severity of ILD, aggressive GORD treatment, in particular with a combination of PPI and H2RA, is associated with improved survival in those with SSc-ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-024-03355-0","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:02:09Z","timestamp":1719273729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"A.","family":"Quinlivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ferdowsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sahhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G-S.","family":"Ngian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Apostolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"Host","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Basnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Morrisroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"2","key":"3355_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.semarthrit.2007.10.010","volume":"38","author":"YS Gu","year":"2008","unstructured":"Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum. 2008;38(2):132\u201360.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3355_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MCG.0b013e318042d625","volume":"42","author":"EC Ebert","year":"2008","unstructured":"Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol. 2008;42(1):5\u201312.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"3355_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40744-021-00382-0","volume":"8","author":"B Li","year":"2021","unstructured":"Li B, Yan J, Pu J, Tang J, Xu S, Wang X. Esophageal dysfunction in systemic sclerosis: an update. Rheumatol Ther. 2021;8(4):1535\u201349.","journal-title":"Rheumatol Ther"},{"issue":"2_suppl","key":"3355_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2397198320903867","volume":"5","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova SI, Denton CP. Pathogenesis of systemic sclerosis associated interstitial lung disease. J Scleroderma Relat Disord. 2020;5(2_suppl):6\u201316.","journal-title":"J Scleroderma Relat Disord"},{"issue":"5","key":"3355_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1164\/rccm.200808-1359OC","volume":"179","author":"E Savarino","year":"2009","unstructured":"Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179(5):408\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3355_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/CPM.0000000000000031","volume":"21","author":"JS Lee","year":"2014","unstructured":"Lee JS. The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med. 2014;21(2):81\u20135.","journal-title":"Clin Pulm Med"},{"issue":"3","key":"3355_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.semarthrit.2010.03.002","volume":"40","author":"RB Christmann","year":"2010","unstructured":"Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40(3):241\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"3355_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S2665-9913(22)00183-7","volume":"4","author":"M Hughes","year":"2022","unstructured":"Hughes M, Allanore Y, Baron M, Del Galdo F, Denton CP, Frech T, et al. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. Lancet Rheumatol. 2022;4(11):795\u2013803.","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"3355_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. J Scleroderma Relat Disord. 2021;6(1):11\u201320.","journal-title":"J Scleroderma Relat Disord"},{"issue":"10","key":"3355_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/resp.13309","volume":"23","author":"TA Winstone","year":"2018","unstructured":"Winstone TA, Hague CJ, Soon J, Sulaiman N, Murphy D, Leipsic J, et al. Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. Respirology. 2018;23(10):921\u20136.","journal-title":"Respirology"},{"issue":"1","key":"3355_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2013-203889","volume":"74","author":"G Lepri","year":"2015","unstructured":"Lepri G, Guiducci S, Bellando-Randone S, Giani I, Bruni C, Blagojevic J, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS\/EUSTAR centre. Ann Rheum Dis. 2015;74(1):124\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3355_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s10067-018-4026-1","volume":"37","author":"S Vettori","year":"2018","unstructured":"Vettori S, Tolone S, Capocotta D, Chieffo R, Giacco V, Valentini G, et al. Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clin Rheumatol. 2018;37(5):1239\u201347.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3355_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Official J Am College Gastroenterol. 2022;117(1):27\u201356.","journal-title":"Official J Am College Gastroenterol"},{"issue":"6 Suppl 86","key":"3355_CR14","first-page":"214","volume":"32","author":"N Hansi","year":"2014","unstructured":"Hansi N, Thoua N, Carulli M, Chakravarty K, Lal S, Smyth A, et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):214\u201321.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3355_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12890-019-0846-2","volume":"19","author":"HE Jo","year":"2019","unstructured":"Jo HE, Corte TJ, Glaspole I, Grainge C, Hopkins PMA, Moodley Y, et al. Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulm Med. 2019;19(1):84.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"3355_CR16","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.21037\/jtd-21-771","volume":"13","author":"M Yang","year":"2021","unstructured":"Yang M, Dong J, An J, Liu L, Chen L. Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. J Thorac Dis. 2021;13(10):5776\u201387.","journal-title":"J Thorac Dis"},{"issue":"2","key":"3355_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.chest.2020.08.2080","volume":"159","author":"T Tran","year":"2021","unstructured":"Tran T, Assayag D, Ernst P, Suissa S. Effectiveness of proton pump inhibitors in idiopathic pulmonary fibrosis: a population-based cohort study. Chest. 2021;159(2):673\u201382.","journal-title":"Chest"},{"issue":"5","key":"3355_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","volume":"1","author":"JS Lee","year":"2013","unstructured":"Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369\u201376.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3355_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.5056\/jnm15192","volume":"22","author":"CM Lee","year":"2016","unstructured":"Lee CM, Lee DH, Ahn BK, Hwang JJ, Yoon H, Shin CM, et al. Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis. J Neurogastroenterol Motil. 2016;22(3):444\u201351.","journal-title":"J Neurogastroenterol Motil"},{"issue":"2","key":"3355_CR20","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3355_CR21","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/rheumatology\/kead023","volume":"62","author":"M Kreuter","year":"2023","unstructured":"Kreuter M, Bonella F, Blank N, Riemekasten G, M\u00fcller-Ladner U, Henes J, et al. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. Rheumatology. 2023;62(9):3067\u201374.","journal-title":"Rheumatology."},{"issue":"11","key":"3355_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3355_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.5603\/KP.2015.0242","volume":"73","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Kardiol Pol (Polish Heart Journal). 2015;73(12):1127\u2013206.","journal-title":"Kardiol Pol (Polish Heart Journal)"},{"issue":"1","key":"3355_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-57636-0","volume":"10","author":"C Foocharoen","year":"2020","unstructured":"Foocharoen C, Chunlertrith K, Mairiang P, Mahakkanukrauh A, Suwannaroj S, Namvijit S, et al. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. Sci Rep. 2020;10(1):1\u20139.","journal-title":"Sci Rep"},{"issue":"2","key":"3355_CR25","doi-asserted-by":"publisher","first-page":"02","DOI":"10.1111\/nmo.13247","volume":"30","author":"EK Stern","year":"2018","unstructured":"Stern EK, Carlson DA, Falmagne S, Hoffmann AD, Carns M, Pandolfino JE, et al. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil. 2018;30(2):02.","journal-title":"Neurogastroenterol Motil"},{"issue":"12","key":"3355_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/phar.1665","volume":"35","author":"M Abdul-Hussein","year":"2015","unstructured":"Abdul-Hussein M, Freeman J, Castell D. Concomitant administration of a histamine2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression. Pharmacotherapy. 2015;35(12):1124\u20139.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"3355_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/MCG.0b013e31814a4e5c","volume":"42","author":"I Mainie","year":"2008","unstructured":"Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676\u20139.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"3355_CR28","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/acr.25070","volume":"75","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Tashkin DP, Leng M, Kim GH, Goldin J, Roth MD. Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Care Res. 2023;75(8):1690\u20137.","journal-title":"Arthritis Care Res."},{"key":"3355_CR29","doi-asserted-by":"publisher","first-page":"106482","DOI":"10.1016\/j.rmed.2021.106482","volume":"185","author":"R Hurtubise","year":"2021","unstructured":"Hurtubise R, Hudson M, Gyger G, Wang M, Steele RJ, Baron M, et al. Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. Respir Med. 2021;185:106482.","journal-title":"Respir Med"},{"issue":"5","key":"3355_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","volume":"11","author":"WK Lo","year":"2013","unstructured":"Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483\u201390.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03355-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:08:18Z","timestamp":1719274098000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03355-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each participant gives consent to be part of the ASCS with ethical approval obtained St Vincent\u2019s Hospital Melbourne Ethics Committee (LRR 012\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}